Meliane (Ethinylestradiol, Gestodene)

Ethinylestradiol provides estrogenic activity that, together with gestodene’s progestogenic effect, suppresses the hypothalamic‑pituitary release of luteinising hormone and follicle‑stimulating hormone. This suppression blocks follicular development, prevents ovulation, and creates cervical mucus and endometrial changes that reduce the chance of fertilisation and implantation.

The dosing regimen for Meliane is determined by the prescribing healthcare professional. Typically, it is taken as a daily tablet according to a fixed schedule, but the exact number of tablets and cycle length should follow the prescriber’s instructions and the product’s labeling.

Meliane is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as hormonal components may pass into breast milk and affect the infant. Women should discontinue use if they become pregnant.

To request Meliane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meliane contains ethinylestradiol and gestodene, a low‑dose progestin that offers a favorable bleeding profile and lower androgenic activity compared with some older formulations. Compared with alternatives that use higher‑dose estrogen or different progestins, Meliane may provide similar contraceptive efficacy with potentially fewer estrogen‑related side effects.

Meliane tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Meliane is taken orally, usually once daily at the same time each day. The tablets are swallowed with water and should be started according to the prescriber’s schedule, often on the first day of the menstrual period or as directed in the prescribing information.

The most serious risks include venous and arterial thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Additional severe concerns are hypertension, liver tumors, gallbladder disease, and rare allergic reactions. Patients should be educated on warning signs and seek immediate medical attention if they occur.

Meliane is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active or severe liver disease, known or suspected breast cancer, and in smokers over 15 cigarettes per day. It should also be avoided during pregnancy and in individuals with known hypersensitivity to any component of the tablet.